ENTA’s preclinical NASH candidates are “10-500 times as potent as OCA,” according to the JPM webcast (21-minute mark). The guidance is to select a lead compound during 2015.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.